Linked Life Data

18379458

Source:http://linkedlifedata.com/resource/pubmed/id/18379458

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2008-4-1
pubmed:abstractText
Neuromidin (ipidacrin) was administered to 41 patients, aged 51-79 years, with mild cognitive impairment (MSI) (19) and vascular dementia (22). The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment). Cognitive functioning was assessed using some clinical scales (CGI, MMSE, GDS etc) and common neuropsychological tests at the base-line and on the 3rd and 6th month of the treatment. A statistically significant therapeutic effect of neuromidin was revealed in both types of cognitive disorders, with the maximal improvement on the first 3 months and further maintenance of the effect. The most distinct dynamics was observed for memory, attention, abstract reasoning, constructive abilities and general mental activity. The drug was well tolerated.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1997-7298
pubmed:author
pubmed:issnType
Print
pubmed:volume
107
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
20-6
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Neuromidin in the treatment of vascular cognitive disorders].
pubmed:publicationType
Journal Article, Comparative Study, English Abstract